HIV Dyslipidemia HIV Dyslipidemia
Conditions
Interventions
Lipid profiles, weight, and waist circumference are followed at 12 and after switching EFV to DTG-based regimen.
Treatment
Switching group
Sponsors
Khon Kaen university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: This is a prospective, open-label, cohort study in HIV-1 infected adults aged more than18 years who have undergone at least six months of EFV-based therapy, have HIV-1 RNA levels less than 50 copies/mL for more than 6 months before switching, and are diagnosed with dyslipidemia or have risk factors for atherosclerosis cardiovascular disease (ASCVD) based on modified National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines.
Exclusion criteria
Exclusion criteria: Exclusion criteria are pregnancy or breastfeeding, active opportunistic infections, or taking metformin more than 1,000 mg/day, rifampicin, St. john's wort, antiarrhythmic drugs (e.g., dofetilide, pilsicainide), antiepileptic drugs (e.g., carbamazepine, oxcarbazepine, phenytoin, phenobarbital), or medications or supplements containing polyvalent cations (e.g., magnesium, aluminum, cation-containing antacids or laxatives, sucralfate, buffered medications).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid profiles 24 weeks mg/dL,Weight 24 weeks Kg,Waist 24 weeks cm | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profiles 12 weeks mg/dL,Weight 12 weeks Kg,Waist 12 weeks cm | — |
Countries
Thailand
Contacts
Public ContactAtibordee Meesing
Faculty of Medicine, Khon Kaen University
Outcome results
None listed